Concepedia
Statistics
Publications
19
Citations
677
H-Index
16
Active since
1989
Affiliations
Pfizer (United States)(Current)
University of Aberdeen
University of Miami
Burroughs Wellcome Fund
Agouron Institute
Mary Collier is an author at Pfizer (United States) specializing in medicine, oncology, and pharmacology.
Publications per year
1989–2013
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
Giuseppe Curigliano, Xavier Pivot, Anthony Elias et al. · The Breast · 2013 · 90 citations
Medicine, Oncology, Pharmacotherapy +9
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)
Kathy D. Miller, HJ Burstein, Anthony Elias et al. · Journal of Clinical Oncology · 2005 · 75 citations
Medicine, Oncology, Pharmacology +2
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.
Leslie R. Laufman, Ronald M. Bukowski, Mary Collier et al. · Journal of Clinical Oncology · 1993 · 59 citations
Medicine, Oncology, Pharmacology +15
Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor
Kenneth R. Hande, Mary Collier, Linda J. Paradiso et al. · Clinical Cancer Research · 2004 · 52 citations · Full text
Medicine, Oncology, Pharmacology +11
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer
Mark Kozloff, Ellen Chuang, Alex Starr et al. · Annals of Oncology · 2009 · 48 citations · Full text
Medicine, Oncology, Pharmacology +14
1–5 of 19